Anton Vmb Schattenberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Anton Vmb Schattenberg has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
T De Witte
12 shared publications- Theo De Witte
Department of Internal Medicine, University Hospital Nijmegen, The Netherlands
5 shared publications F Preijers
Central Hematology Laboratory, University Medical Centre Nijmegen, Nijmegen, The Netherlands
4 shared publicationsB M Bär
3 shared publicationsJ Raemaekers
3 shared publications- Nicolaas Schaap
Department of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands
3 shared publications
Latest Publications
- 1 November 2010
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 46 (8) , 1071-1076
Adult metachromatic leukodystrophy treated by allo-SCT and a review of the literature
Five patients with adult-onset metachromatic leukodystrophy (MLD) underwent allo-SCT. Conditioning was reduced in intensity and grafts were obtained from voluntary unrelated donors. All but one graft were depleted of T-lymphocytes. Patient age at transplantation varied from 18 to 29 (median, 27) years. Two patients rejected their graft and MLD progressed. The recipient of the unmanipulated graft converted to complete donor chimerism with normalization of arylsulphatase A (ARSA) levels. Despite ARSA normalization, he deteriorated. Another patient was a mixed chimera. Following escalated doses of donor lymphocyte infusions he converted to complete donor chimerism. His levels of ARSA correlated positively with the percentage of donor cells and MLD was not progressive. The fifth patient died after 35 days from complications associated with GVHD. We conclude that results of allo-SCT in symptomatic MLD patients are poor. However, allo-SCT may stop progression of MLD in selected patients.
- 1 November 2010
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 46 (8) , 1071-1076
Adult metachromatic leukodystrophy treated by allo-SCT and a review of the literature
Five patients with adult-onset metachromatic leukodystrophy (MLD) underwent allo-SCT. Conditioning was reduced in intensity and grafts were obtained from voluntary unrelated donors. All but one graft were depleted of T-lymphocytes. Patient age at transplantation varied from 18 to 29 (median, 27) years. Two patients rejected their graft and MLD progressed. The recipient of the unmanipulated graft converted to complete donor chimerism with normalization of arylsulphatase A (ARSA) levels. Despite ARSA normalization, he deteriorated. Another patient was a mixed chimera. Following escalated doses of donor lymphocyte infusions he converted to complete donor chimerism. His levels of ARSA correlated positively with the percentage of donor cells and MLD was not progressive. The fifth patient died after 35 days from complications associated with GVHD. We conclude that results of allo-SCT in symptomatic MLD patients are poor. However, allo-SCT may stop progression of MLD in selected patients.
- 28 February 2009
- Vol. 153 (9) , 380-5
[Allogenic stem cell transplantation in the Netherlands].
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 7036
Impact of the intensity of conditioning regimen in 144 patients with follicular lymphoma (FL) receiving a matched unrelated donor stem cell transplant (MUD-SCT): An analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (LWP-EBMT)
7036 Background: Matched unrelated donor stem cell transplant (MUD-SCT) provides the only potentially curative option for patients with follicular lymphoma (FL) who fail conventional therapies and do not have a sibling donor. Methods: The data of 144 patients with FL treated with reduced-intensity conditioning (RIC: 93) or conventional myeloablative (CONV: 51) MUD-SCT between 1991 and 2005 and included in the EBMT registry are reported. Results: Median time from diagnosis to MUD-SCT was 46 months and the median number of previous treatment lines was 4, including an autograft in 47% of patients. RIC recipients were significantly older, with a longer interval from diagnosis to MUD-SCT and had failed a previous autograft more frequently than CONV recipients. Non-relapse mortality (NRM) at 3 years was 34% and 46% for the RIC and the CONV groups, respectively (p<0.001). No differences were found in the risk of recurrence according to the conditioning regimen. Patients receiving a RIC procedure had a significantly longer progression-free survival (3-year PFS: 43%) and overall survival (3-year OS: 49%) than CONV recipients (3-year PFS: 35% -p=0.004-; 3-year OS: 40% -p=0.001-). Conclusions: This study demonstrates that RIC-MUD results, even in heavily pre-treated populations, in a significantly prolonged PFS. No significant financial relationships to disclose.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 7036
Impact of the intensity of conditioning regimen in 144 patients with follicular lymphoma (FL) receiving a matched unrelated donor stem cell transplant (MUD-SCT): An analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (LWP-EBMT)
7036 Background: Matched unrelated donor stem cell transplant (MUD-SCT) provides the only potentially curative option for patients with follicular lymphoma (FL) who fail conventional therapies and do not have a sibling donor. Methods: The data of 144 patients with FL treated with reduced-intensity conditioning (RIC: 93) or conventional myeloablative (CONV: 51) MUD-SCT between 1991 and 2005 and included in the EBMT registry are reported. Results: Median time from diagnosis to MUD-SCT was 46 months and the median number of previous treatment lines was 4, including an autograft in 47% of patients. RIC recipients were significantly older, with a longer interval from diagnosis to MUD-SCT and had failed a previous autograft more frequently than CONV recipients. Non-relapse mortality (NRM) at 3 years was 34% and 46% for the RIC and the CONV groups, respectively (p<0.001). No differences were found in the risk of recurrence according to the conditioning regimen. Patients receiving a RIC procedure had a significantly longer progression-free survival (3-year PFS: 43%) and overall survival (3-year OS: 49%) than CONV recipients (3-year PFS: 35% -p=0.004-; 3-year OS: 40% -p=0.001-). Conclusions: This study demonstrates that RIC-MUD results, even in heavily pre-treated populations, in a significantly prolonged PFS. No significant financial relationships to disclose.
- 1 November 2006
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 18 (6) , 667-670
Differences between the different conditioning regimens for allogeneic stem cell transplantation
The aim of this article is to compare the differences in efficacy and toxicity between the various conditioning regimens for allogeneic stem cell transplantation. Several studies, all retrospective, that compare the impact of various different conditioning regimens amongst each other are presented. Reduced intensity conditioning apparently lowered transplant-related mortality in patients with minimal residual disease who were at high risk for treatment-related mortality. In contrast, patients with active disease could only be salvaged when a myeloablative conditioning regimen was used. By consequence, it was concluded that patients without contraindications for a myeloablative conditioning regimen should not receive reduced regimens outside a prospective randomized trial. Despite high expectations, non-myeloablative conditioning regimens and regimens that have been reduced in intensity did not prove to be superior in survival when the outcomes were compared with those obtained with conventional myeloablative conditioning. Randomized prospective studies are needed to explore the appropriate niche for the various different regimens.
- 1 November 2006
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 18 (6) , 667-670
Differences between the different conditioning regimens for allogeneic stem cell transplantation
The aim of this article is to compare the differences in efficacy and toxicity between the various conditioning regimens for allogeneic stem cell transplantation. Several studies, all retrospective, that compare the impact of various different conditioning regimens amongst each other are presented. Reduced intensity conditioning apparently lowered transplant-related mortality in patients with minimal residual disease who were at high risk for treatment-related mortality. In contrast, patients with active disease could only be salvaged when a myeloablative conditioning regimen was used. By consequence, it was concluded that patients without contraindications for a myeloablative conditioning regimen should not receive reduced regimens outside a prospective randomized trial. Despite high expectations, non-myeloablative conditioning regimens and regimens that have been reduced in intensity did not prove to be superior in survival when the outcomes were compared with those obtained with conventional myeloablative conditioning. Randomized prospective studies are needed to explore the appropriate niche for the various different regimens.
- 20 March 2006
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 37 (9) , 831-836
Quality of life, reproduction and sexuality after stem cell transplantation with partially T-cell-depleted grafts and after conditioning with a regimen including total body irradiation
Thirty-four men and 36 women (median age 43 and 45 years, respectively) underwent stem cell transplantation (SCT) for acute leukaemia in first complete remission or chronic myelogenous leukaemia in first chronic phase between 1981 and 2001 from HLA-identical siblings. The conditioning regimen included TBI and all grafts were partially depleted of T cells. Changes in quality of life (QOL), reproduction and sexuality were studied using a questionnaire, and the previously given information related to these problems was assessed. In addition, endocrine status was assessed and semen analysis was performed. After SCT, patients reported less energy (n=50) and a deterioration in the job situation (n=31). Patients experienced a negative change in sexual relations (n=41). Important problems of sexual dysfunction were vaginal dryness in women (n=19) and erectile dysfunction in men (n=16). None of the patients was fertile based on their gonadotrophin levels, sperm concentrations and reproductive outcomes. Women experienced climacteric symptoms (n=24). Quality of life was negatively influenced by these changes. One-fifth of the patients were not satisfied with the information given with regard to reproduction, premature menopause and sexual problems.
- 20 March 2006
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 37 (9) , 831-836
Quality of life, reproduction and sexuality after stem cell transplantation with partially T-cell-depleted grafts and after conditioning with a regimen including total body irradiation
Thirty-four men and 36 women (median age 43 and 45 years, respectively) underwent stem cell transplantation (SCT) for acute leukaemia in first complete remission or chronic myelogenous leukaemia in first chronic phase between 1981 and 2001 from HLA-identical siblings. The conditioning regimen included TBI and all grafts were partially depleted of T cells. Changes in quality of life (QOL), reproduction and sexuality were studied using a questionnaire, and the previously given information related to these problems was assessed. In addition, endocrine status was assessed and semen analysis was performed. After SCT, patients reported less energy (n=50) and a deterioration in the job situation (n=31). Patients experienced a negative change in sexual relations (n=41). Important problems of sexual dysfunction were vaginal dryness in women (n=19) and erectile dysfunction in men (n=16). None of the patients was fertile based on their gonadotrophin levels, sperm concentrations and reproductive outcomes. Women experienced climacteric symptoms (n=24). Quality of life was negatively influenced by these changes. One-fifth of the patients were not satisfied with the information given with regard to reproduction, premature menopause and sexual problems.
- 1 November 2005
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 17 (6) , 617-621
Cellular adoptive immunotherapy after allogeneic stem cell transplantation
This review presents the role of donor lymphocyte infusion, natural killer cells, and dendritic cells in cellular immunotherapy after allogeneic stem cell transplantation. It becomes increasingly possible to infuse more specialized subsets of lymphocyte cells after transplantation. The infusion of natural killer cells, especially in non human leukocyte antigen-identical transplantation, may become an important tool in enhancing the graft-versus-tumor effect. Vaccination of patients after stem cell transplantation with autologous-derived dendritic cells merits further investigation. Stem cell transplantation has evolved to a specialized form of immunotherapy.
- 1 November 2005
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 17 (6) , 617-621
Cellular adoptive immunotherapy after allogeneic stem cell transplantation
This review presents the role of donor lymphocyte infusion, natural killer cells, and dendritic cells in cellular immunotherapy after allogeneic stem cell transplantation. It becomes increasingly possible to infuse more specialized subsets of lymphocyte cells after transplantation. The infusion of natural killer cells, especially in non human leukocyte antigen-identical transplantation, may become an important tool in enhancing the graft-versus-tumor effect. Vaccination of patients after stem cell transplantation with autologous-derived dendritic cells merits further investigation. Stem cell transplantation has evolved to a specialized form of immunotherapy.
- 5 April 2004
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 33 (11) , 1115-1121
Addition of ATG to the conditioning regimen is a major determinant for outcome after transplantation with partially lymphocyte-depleted grafts from voluntary unrelated donors
- 5 April 2004
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 33 (11) , 1115-1121
Addition of ATG to the conditioning regimen is a major determinant for outcome after transplantation with partially lymphocyte-depleted grafts from voluntary unrelated donors
- 15 June 2000
- Vol. 95 (12) , 3693-701
A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease.
This study evaluated the anti-graft versus host disease (GVHD) potential of a combination of immunotoxins (IT), consisting of a murine CD3 (SPV-T3a) and CD7 (WT1) monoclonal antibody both conjugated to deglycosylated ricin A. In vitro efficacy data demonstrated that these IT act synergistically, resulting in an approximately 99% elimination of activated T cells at 10(-8 )mol/L (about 1.8 microg/mL). Because most natural killer (NK) cells are CD7(+), NK activity was inhibited as well. Apart from the killing mediated by ricin A, binding of SPV-T3a by itself impaired in vitro cytotoxic T-cell cytotoxicity. Flow cytometric analysis revealed that this was due to both modulation of the CD3/T-cell receptor complex and activation-induced cell death. These results warranted evaluation of the IT combination in patients with refractory acute GVHD in an ongoing pilot study. So far, 4 patients have been treated with 3 to 4 infusions of 2 or 4 mg/m(2) IT combination, administered intravenously at 48-hour intervals. The T(1/2) was 6.7 hours, and peak serum levels ranged from 258 to 3210 ng/mL. Drug-associated side effects were restricted to limited edema, fever, and a modest rise of creatine kinase levels. One patient developed low-titer antibodies against ricin A. Infusions were associated with an immediate drop of circulating T cells, followed by a more gradual but continuing elimination of T/NK cells. One patient mounted an extensive CD8 T-cell response directly after treatment, not accompanied with aggravating GVHD. Two patients showed nearly complete remission of GVHD, despite unresponsiveness to the extensive pretreatment. These findings justify further investigation of the IT combination for treatment of diseases mediated by T cells. (Blood. 2000;95:3693-3701)
- 15 June 2000
- Vol. 95 (12) , 3693-701
A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease.
This study evaluated the anti-graft versus host disease (GVHD) potential of a combination of immunotoxins (IT), consisting of a murine CD3 (SPV-T3a) and CD7 (WT1) monoclonal antibody both conjugated to deglycosylated ricin A. In vitro efficacy data demonstrated that these IT act synergistically, resulting in an approximately 99% elimination of activated T cells at 10(-8 )mol/L (about 1.8 microg/mL). Because most natural killer (NK) cells are CD7(+), NK activity was inhibited as well. Apart from the killing mediated by ricin A, binding of SPV-T3a by itself impaired in vitro cytotoxic T-cell cytotoxicity. Flow cytometric analysis revealed that this was due to both modulation of the CD3/T-cell receptor complex and activation-induced cell death. These results warranted evaluation of the IT combination in patients with refractory acute GVHD in an ongoing pilot study. So far, 4 patients have been treated with 3 to 4 infusions of 2 or 4 mg/m(2) IT combination, administered intravenously at 48-hour intervals. The T(1/2) was 6.7 hours, and peak serum levels ranged from 258 to 3210 ng/mL. Drug-associated side effects were restricted to limited edema, fever, and a modest rise of creatine kinase levels. One patient developed low-titer antibodies against ricin A. Infusions were associated with an immediate drop of circulating T cells, followed by a more gradual but continuing elimination of T/NK cells. One patient mounted an extensive CD8 T-cell response directly after treatment, not accompanied with aggravating GVHD. Two patients showed nearly complete remission of GVHD, despite unresponsiveness to the extensive pretreatment. These findings justify further investigation of the IT combination for treatment of diseases mediated by T cells. (Blood. 2000;95:3693-3701)
- 1 September 1998
- Vol. 92 (5) , 1832-6
Allogeneic bone marrow transplantation for low-grade lymphoma.
Advanced low-grade lymphomas are usually incurable with conventional-dose chemotherapy. It is uncertain whether cures are possible with high-dose therapy and bone marrow transplant from a human leukocyte antigen (HLA)-identical sibling. We sought to determine the outcome of HLA-identical sibling bone marrow transplants in advanced low-grade lymphoma in an observational study of 113 patients conducted at 50 centers participating in the International Bone Marrow Transplant Registry (IBMTR). The median patient age was 38 years (range, 15 to 61). Eighty percent had stage IV disease at the time of transplantation. The median number of prior chemotherapy regimens was two (range, 0 to 5). Thirty-eight percent had refractory disease and 29% a Karnofsky performance score (KPS) less than 80%. All patients underwent allogeneic bone marrow transplantation from a HLA-identical sibling donor. The conditioning regimen included total-body irradiation (TBI) in 82% of patients; cyclosporine was used for graft-versus-host disease prophylaxis in 74%. Survival, disease-free survival, recurrence rate, treatment-related mortality, and causes of death were determined. Three-year probabilities of recurrence, survival, and disease-free survival were 16% (95% confidence interval [CI], 9% to 27%), 49% (95% CI, 39% to 60%), and 49% (95% CI, 39% to 59%), respectively. Higher survival was associated with pretransplant KPS >/=90%, chemotherapy-sensitive disease, use of a TBI-containing conditioning regimen, and age less than 40 years. We conclude that high-dose therapy followed by transplantation from a HLA-identical sibling leads to prolonged survival in some patients with advanced low-grade lymphoma. Most mortality is treatment-related, and recurrences are rare.
- 1 September 1998
- Vol. 92 (5) , 1832-6
Allogeneic bone marrow transplantation for low-grade lymphoma.
Advanced low-grade lymphomas are usually incurable with conventional-dose chemotherapy. It is uncertain whether cures are possible with high-dose therapy and bone marrow transplant from a human leukocyte antigen (HLA)-identical sibling. We sought to determine the outcome of HLA-identical sibling bone marrow transplants in advanced low-grade lymphoma in an observational study of 113 patients conducted at 50 centers participating in the International Bone Marrow Transplant Registry (IBMTR). The median patient age was 38 years (range, 15 to 61). Eighty percent had stage IV disease at the time of transplantation. The median number of prior chemotherapy regimens was two (range, 0 to 5). Thirty-eight percent had refractory disease and 29% a Karnofsky performance score (KPS) less than 80%. All patients underwent allogeneic bone marrow transplantation from a HLA-identical sibling donor. The conditioning regimen included total-body irradiation (TBI) in 82% of patients; cyclosporine was used for graft-versus-host disease prophylaxis in 74%. Survival, disease-free survival, recurrence rate, treatment-related mortality, and causes of death were determined. Three-year probabilities of recurrence, survival, and disease-free survival were 16% (95% confidence interval [CI], 9% to 27%), 49% (95% CI, 39% to 60%), and 49% (95% CI, 39% to 59%), respectively. Higher survival was associated with pretransplant KPS >/=90%, chemotherapy-sensitive disease, use of a TBI-containing conditioning regimen, and age less than 40 years. We conclude that high-dose therapy followed by transplantation from a HLA-identical sibling leads to prolonged survival in some patients with advanced low-grade lymphoma. Most mortality is treatment-related, and recurrences are rare.
- 1 June 1998
- p. S66-70
A retrospective Dutch study comparing T cell-depleted allogeneic blood stem cell transplantation vs T cell-depleted allogeneic bone marrow transplantation.
Retrospectively, a cohort of 43 hematological patients receiving an allogeneic T cell-depleted (TCD)-PBSCT between 1994 and 1997, was compared to a cohort of 435 patients, who received an allogeneic TCD-BMT between 1990 and 1996. Both cohorts were comparable with respect to diagnosis, risk status, age and sex. PB grafts contained four to five times more hematopoietic progenitor cells and T cells as compared to BM grafts. T cell depletion was performed by either elutriation, CD34 selection, E-rosetting, or Campath serotherapy. Conditioning was cyclophosphamide/TBI in the majority of patients of both cohorts. All patients received cyclosporin A as GVHD prophylaxis until day 90 post-transplant. Engraftment was significantly faster in the PBPCT cohort with a median time to neutrophil recovery (>0.5 x 10(9)/l) of 16 vs 21 days in the BMT cohort (P = 0.0009). Platelet recovery to 50 x 10(9)/l was 16 vs 34 days for the PB and BM cohort respectively (P < 0.0001). A median percentage of 76% of BMT patients recovered to 50 within 100 days post-BMT vs 91% of patients receiving a PB graft. The incidence of acute GVHD grades II, III and IV was similar in both cohorts. In contrast, the probability of developing chronic GVHD was 21% in the BM cohort vs 37% in the PB cohort. Relapse incidence was reduced in the PB cohort (9 vs 29%), while treatment-related mortality was not different for both cohorts. These favorable results require confirmation by a prospective randomized trial, which is currently being performed by several European centers.
- 1 June 1998
- p. S66-70
A retrospective Dutch study comparing T cell-depleted allogeneic blood stem cell transplantation vs T cell-depleted allogeneic bone marrow transplantation.
Retrospectively, a cohort of 43 hematological patients receiving an allogeneic T cell-depleted (TCD)-PBSCT between 1994 and 1997, was compared to a cohort of 435 patients, who received an allogeneic TCD-BMT between 1990 and 1996. Both cohorts were comparable with respect to diagnosis, risk status, age and sex. PB grafts contained four to five times more hematopoietic progenitor cells and T cells as compared to BM grafts. T cell depletion was performed by either elutriation, CD34 selection, E-rosetting, or Campath serotherapy. Conditioning was cyclophosphamide/TBI in the majority of patients of both cohorts. All patients received cyclosporin A as GVHD prophylaxis until day 90 post-transplant. Engraftment was significantly faster in the PBPCT cohort with a median time to neutrophil recovery (>0.5 x 10(9)/l) of 16 vs 21 days in the BMT cohort (P = 0.0009). Platelet recovery to 50 x 10(9)/l was 16 vs 34 days for the PB and BM cohort respectively (P < 0.0001). A median percentage of 76% of BMT patients recovered to 50 within 100 days post-BMT vs 91% of patients receiving a PB graft. The incidence of acute GVHD grades II, III and IV was similar in both cohorts. In contrast, the probability of developing chronic GVHD was 21% in the BM cohort vs 37% in the PB cohort. Relapse incidence was reduced in the PB cohort (9 vs 29%), while treatment-related mortality was not different for both cohorts. These favorable results require confirmation by a prospective randomized trial, which is currently being performed by several European centers.